-Reuters
RegenXbio’s Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence
Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a
Fed’s Williams Says Long Term Interest Rates Are Still Historically Low
-Reuters
Related Posts
Huize Expands Globally with Acquisition of Vietnam’s Global Care, Financial Terms Undisclosed
Huize Holding Limited, ("Huize" or the "Company") (NASDAQ:HUIZ), a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through
Credit Suisse Maintains Neutral on Church & Dwight Co, Lowers Price Target to $92
Credit Suisse analyst Kaumil Gajrawala maintains Church & Dwight Co (NYSE:CHD) with a Neutral and lowers the price target from $100 to $92.
Raymond James Downgrades Centerspace to Market Perform
Raymond James analyst Buck Horne downgrades Centerspace (NYSE:CSR) from Outperform to Market Perform.